EGFR mutations are most commonly associated with non-small cell lung cancer (NSCLC). These mutations can make cancer cells more responsive to targeted therapies. Glioblastomas, a type of brain cancer, also frequently exhibit EGFR amplification. Additionally, EGFR mutations are seen in colorectal cancers, head and neck squamous cell carcinomas, and some breast cancers.
